Universe Pharmaceuticals INC (UPC) Fair Value 2026

UPC · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

1.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (100/100)

Quick Summary — As of 2026-08-28, Universe Pharmaceuticals INC (UPC) trades at $4.90. QOC: 1.8/10. Value Trap Risk: 100/100 (DANGER). 1/13 models active.

Key Facts

Ticker
UPC
Price
$4.90
Quality Score
1.8/10
Value Trap Risk
100/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +17.1% upside with 12% confidence
Risk: Value Trap score of 100 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give UPC?

1 Intrinsic Value Models vs. Current Price ($4.90)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Low Conviction
 $5.74 +17.1%

All Models Active

All 1 models are displayed above.

What Is Universe Pharmaceuticals INC (UPC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Universe Pharmaceuticals INC's intrinsic value is estimated at a median fair value of $5.74. At a current market price of $4.90, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +17.1%.

What Do the Models Say About UPC?

1 of 13 models are currently active for UPC. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does UPC Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, UPC ranks #110 by Quality of Company score. CirclFi's QOC score of 1.8/10 evaluates 32 fundamental signals. A score of 1.8 signals below-average fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to healthcare company businesses. For Universe Pharmaceuticals INC, metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is UPC a Value Trap?

CirclFi's Value Trap algorithm assigns UPC a score of 100/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Universe Pharmaceuticals INC. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Universe Pharmaceuticals INC earns a quality score of 1.8/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. However, our Value Trap algorithm flags elevated risk — suggesting that apparent cheapness may mask deteriorating fundamentals.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every UPC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across UPC's 1 active models, average confidence is 12%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Universe Pharmaceuticals INC Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

10 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

BGMBGM Group Ltd.QOC 1.9SXTCChina SXT Pharmaceuticals, Inc.QOC 1.4KMDAKamada Ltd.QOC 2.6AKANAkanda Corp.QOC 1.3HCMHUTCHMED (China) LimitedQOC 2.7UTHRUnited Therapeutics CorporationQOC 9.6ELANElanco Animal Health IncorporatedQOC 7.2INISRadnostix, Inc.QOC 6.1RGCRegencell Bioscience Holdings LimitedQOC 4.8AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: BGM · SXTC · KMDA · AKAN · HCM · UTHR · ELAN · INIS · RGC · AMPH

Which Other Stocks Have a Similar Quality Score to UPC?

7 companies across all industries closest to UPC’s Quality of Company score of 1.8/10.

RDGTRidgetech, Inc.QOC 1.8TAOPTaoping Inc.QOC 1.8NEXRNexera Technologies LtdQOC 1.8AGMHAGM Group Holdings Inc.QOC 1.8RAYAErayak Power Solution Group Inc.QOC 1.8GDHGGolden Heaven Group Holdings Ltd.QOC 1.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RDGT · TAOP · NEXR · AGMH · RAYA · GDHG · NVDA

Where Does UPC Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

UPC is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Universe Pharmaceuticals INC’s Valuation?

What is Universe Pharmaceuticals INC's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Universe Pharmaceuticals INC (UPC). The Quality of Company score is 1.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is UPC overvalued or undervalued right now?

At $4.90, 1 of 1 active models suggest UPC may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Universe Pharmaceuticals INC's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 1.8 mean for UPC?

Universe Pharmaceuticals INC's QOC of 1.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on UPC?

CirclFi analyzes UPC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is UPC a value trap in 2026?

Universe Pharmaceuticals INC's Value Trap score is 100/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Universe Pharmaceuticals INC (UPC) a Quality of Company score of 1.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/UPC/ · Methodology
Primary sources for this UPC valuation
  • Financial statements: Universe Pharmaceuticals INC 10-K and 10-Q filings on SEC EDGAR (CIK 0001809616) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for UPC as of ; valuations recomputed .